A Phase 2 interventional study of PD P 506 A in Onychomycosis, sponsored by photonamic GmbH & Co. KG. Completed at 2 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-19.
Sponsored by photonamic GmbH & Co. KG (formerly part of medac GmbH) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail. Patients will receive four PDT treatments with PD P 506 A in weekly intervals.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
This study's enrollment of 25 is below the median of 60 across 143 interventional studies indexed under Onychomycosis.
Browse Onychomycosis studies →photonamic GmbH & Co. KG is the lead sponsor of 7 studies on the registry; none are open to participants now.
First submitted before photonamic GmbH & Co. KG left medac GmbH.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
Drug: PD P 506 A
PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
Also known as: Alacare®
Percentage of nails with Clinically Complete Cure
The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): * Residual changes of the nail plate compatible with dermatophyte infection * White/yellow or orange brown/patches or streaks in or beneath the nail * Lateral onycholysis with debris in an otherwise clear nail plate * Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".
Time frame: 12 months after last study treatment
Percentage of nails with negative laboratory test results for onychomycosis (KOH test, periodic acid-Schiff (PAS) stain and mycology culture).
Time frame: 12 months after last study treatment
Percentage of nails with Clinically Complete Cure
The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): * Residual changes of the nail plate compatible with dermatophyte infection * White/yellow or orange brown/patches or streaks in or beneath the nail * Lateral onycholysis with debris in an otherwise clear nail plate * Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".
Time frame: 3 and 6 months after last study treatment
Frequency of adverse events
Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Severity (grade1-5) of adverse events
The severity of AEs is defined as: * Grade 1 = mild * Grade 2 = moderate * Grade 3 = severe * Grade 4 = life-threatening * Grade 5 = fatal
Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Frequency of local reactions.
Photodynamic therapy is intended to produce a phototoxic reaction, which is part of the desired effect. After PDT, treated toes may show local reactions such as redness and swelling.
Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Severity (grade1-3) of local reactions.
The severity of local reactions is defined as: * Grade 1 = mild * Grade 2 = moderate * Grade 3 = severe
Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
One photo of each treated toenail at the beginning of each visit
Documentation of the course of the study for each treated toenail.
Time frame: At screening visit (up to 4 weeks before first treatment), during the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2015, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aminolevulinic Acid